Opdivo plus chemo becomes first immunotherapy-based treatment to improve EFS and pCR in NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The neoadjuvant Opdivo (nivolumab) plus chemotherapy showed a statistically significant and clinically meaningful improvement in event-free survival compared to chemotherapy alone in patients with with resectable stage IB to IIIA non-small cell lung cancer, according to a prespecified interim analysis of the phase III CheckMate -816 trial. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents


With growing evidence that molecular characterization of a tumor helps predict a patient’s prognosis and response to specific treatments, biomarker testing has been required or recommended for more than half of the 62 oncology drugs introduced over the past five years. However, health insurance policies don’t always cover tests, thus denying their clients access to precision medicine.
Emergent public-private partnerships (PPPs) have risen to the occasion to streamline and coordinate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. With these monumental efforts have come important public discussions about equitable access and representation in clinical trials (CTs).